Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series

References

• Hellgren K, Smedby KE, Feltelius N, Baecklund E, Askling J. Do rheumatoid arthritis and lymphoma share risk factors? A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum. 2010;62(5):1252–8.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007;34(2):322–31.
   PubMed Web of Science ®Google Scholar
• Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol. 2012;84(2):327–35.
   PubMed Web of Science ®Google Scholar
• Eguchi K, Origuchi T, Takashima H, Iwata K, Katamine S, Nagataki S. High seroprevalence of anti-HTLV-I antibody in rheumatoid arthritis. Arthritis Rheum. 1996;39(3):463–6.
   PubMed Web of Science ®Google Scholar
• Watanabe T. HTLV-1-associated diseases. Int J Hematol. 1997;66(3): 257–78.
   PubMed Web of Science ®Google Scholar
• Nishioka K, Sumida T, Hasunuma T. Human T lymphotropic virus type I in arthropathy and autoimmune disorders. Arthritis Rheum. 1996;39(8):1410–8.
   PubMed Web of Science ®Google Scholar
• Kawano N, Shimoda K, Ishikawa F, Taketomi A, Yoshizumi T, Shimoda S, et al. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation 2006;82(6):840–3.
   PubMed Web of Science ®Google Scholar
• Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, et al. Joint Study on Predisposing Factors of ATL Development investigators. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010;116(8):1211–9.
   PubMed Web of Science ®Google Scholar
• Okayama A, Stuver S, Matsuoka M, Ishizaki J, Tanaka G, Kubuki Y, et al. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer 2004;110(4):621–5.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8.
   PubMed Web of Science ®Google Scholar
• Tanaka G, Okayama A, Watanabe T, Aizawa S, Stuver S, Mueller N, et al. The clonal expansion of human T lymphotropic virus type 1-infected T cells: a comparison between seroconverters and long-term carriers. J Infect Dis. 2005;191(7):1140–47.
   PubMed Web of Science ®Google Scholar
• Etoh K, Tamiya S, Yamaguchi K, Okayama A, Tsubouchi H, Ideta T, et al. Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. Cancer Res. 1997;57(21):4862–7.
   PubMed Web of Science ®Google Scholar
• Terada K, Katamine S, Eguchi K, Moriuchi R, Kita M, Shimada H, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren's syndrome. Lancet 1994;344(8930):1116–9.
   PubMed Web of Science ®Google Scholar
• Sato K, Maruyama I, Maruyama Y, Kitajima I, Nakajima Y, Higaki M, et al. Arthritis in patients infected with human T lymphotropic virus type I. Clinical and immunopathologic features. Arthritis Rheum. 1991; 34(6):714–21.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 2007;17(1):28–32.
   PubMedGoogle Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21(4):343–51.
   PubMed Web of Science ®Google Scholar
• Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2011; 38(11):2346–54.
   PubMed Web of Science ®Google Scholar
• Cavazzana I, Bobbio-Pallavicini F, Franceschini F, Bazzani C, Ceribelli A, Bravi E, et al. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients. Clin Exp Rheumatol 2007;25(5):676–83.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Saijo S, Kioka Y, Nakayama-Yamada J, Itagaki K, Tosu M, et al. Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J Immunol. 1995;155(3):1588–98.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433–9.
   PubMed Web of Science ®Google Scholar
• Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64(5):699–703.
   PubMed Web of Science ®Google Scholar
• Yakova M, Lézin A, Dantin F, Lagathu G, Olindo S, Jean- Baptiste G, et al. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2005;2:4.
   PubMed Web of Science ®Google Scholar